Literature DB >> 29941654

Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation.

Ronilda D'Cunha1, Thanh Bach1, Beth Ann Young1, Peizhi Li2, Demet Nalbant1, Jun Zhang3, Patricia Winokur4, Guohua An5.   

Abstract

The highly variable pharmacokinetics of β-lactam antibiotics and β-lactamase inhibitors poses a significant challenge to clinicians in ensuring appropriate antibiotic doses in critically ill patients. Therefore, routine monitoring of plasma concentrations is important for individualization of antimicrobial therapy. Accordingly, a simple and robust analytical method for the simultaneous measurement of multiple β-lactam antibiotics and β-lactamase inhibitors is highly desirable to ensure quick decisions on dose adjustments. In this study, a sensitive, simple, and robust method for the simultaneous quantification of cefepime, meropenem, piperacillin, and tazobactam in human plasma was developed and rigorously validated according to FDA guidance. Sample extraction was accomplished by simple protein precipitation. Chromatographic separation of analytes was achieved using stepwise gradient elution. Analytes were monitored using tandem mass spectrometry (MS/MS) with a turbo ion spray source in positive multiple-reaction-monitoring mode. The calibration curve ranged from 0.5 to 150 μg/ml for cefepime, 0.1 to 150 μg/ml for meropenem and piperacillin, and 0.25 to 150 μg/ml for tazobactam. Inter- and intraday precision and accuracy, sensitivity, selectivity, dilution integrity, matrix effect, extraction recovery, and hemolysis effect were investigated for all four analytes, and the results met the acceptance criteria. Compared to other reported methods, our method is more robust because of the combination of the following features: (i) a simple sample extraction procedure, (ii) a short sample run time, (iii) a wide dynamic range, and (iv) the small plasma sample volume needed. Since our method already covers β-lactams and a β-lactamase inhibitor with highly heterogeneous physicochemical properties, further antibiotic candidates may easily be incorporated into this multianalyte method.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  LC-MS/MS; assay development; human plasma; validation; β-lactams

Mesh:

Substances:

Year:  2018        PMID: 29941654      PMCID: PMC6125519          DOI: 10.1128/AAC.00859-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Simultaneous determination of seven β-lactam antibiotics in human plasma for therapeutic drug monitoring and pharmacokinetic studies.

Authors:  Fekade Bruck Sime; Michael S Roberts; Jason A Roberts; Thomas A Robertson
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-04-24       Impact factor: 3.205

2.  Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC-MS/MS method with semi-automated sample preparation.

Authors:  Johannes Zander; Barbara Maier; Anna Suhr; Michael Zoller; Lorenz Frey; Daniel Teupser; Michael Vogeser
Journal:  Clin Chem Lab Med       Date:  2015-04       Impact factor: 3.694

3.  Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.

Authors:  Jason A Roberts; Marta Ulldemolins; Michael S Roberts; Brett McWhinney; Jacobus Ungerer; David L Paterson; Jeffrey Lipman
Journal:  Int J Antimicrob Agents       Date:  2010-08-03       Impact factor: 5.283

Review 4.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection.

Authors:  Brett C McWhinney; Steven C Wallis; Tara Hillister; Jason A Roberts; Jeffrey Lipman; Jacobus P J Ungerer
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-05-24       Impact factor: 3.205

6.  International study of the prevalence and outcomes of infection in intensive care units.

Authors:  Jean-Louis Vincent; Jordi Rello; John Marshall; Eliezer Silva; Antonio Anzueto; Claude D Martin; Rui Moreno; Jeffrey Lipman; Charles Gomersall; Yasser Sakr; Konrad Reinhart
Journal:  JAMA       Date:  2009-12-02       Impact factor: 56.272

7.  Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Pierre-François Laterre; Thierry Dugernier; Herbert Spapen; Isabelle Delattre; Xavier Wittebole; Daniel De Backer; Brice Layeux; Pierre Wallemacq; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2010-07-01       Impact factor: 9.097

8.  Simultaneous analysis of antibiotics in biological samples by ultra high performance liquid chromatography-tandem mass spectrometry.

Authors:  Rocío Cazorla-Reyes; Roberto Romero-González; Antonia Garrido Frenich; Manuel Angel Rodríguez Maresca; José Luis Martínez Vidal
Journal:  J Pharm Biomed Anal       Date:  2013-11-15       Impact factor: 3.935

9.  Development and validation of a fast and uniform approach to quantify β-lactam antibiotics in human plasma by solid phase extraction-liquid chromatography-electrospray-tandem mass spectrometry.

Authors:  Pieter Colin; Lies De Bock; Huybrecht T'jollyn; Koen Boussery; Jan Van Bocxlaer
Journal:  Talanta       Date:  2012-10-27       Impact factor: 6.057

10.  Optimization of protein precipitation based upon effectiveness of protein removal and ionization effect in liquid chromatography-tandem mass spectrometry.

Authors:  Cara Polson; Pratibha Sarkar; Bev Incledon; Vanaja Raguvaran; Russell Grant
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-03-05       Impact factor: 3.205

View more
  6 in total

1.  Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 2: Stability Evaluation.

Authors:  Ronilda D'Cunha; Thanh Bach; Beth Ann Young; Peizhi Li; Demet Nalbant; Jun Zhang; Patricia Winokur; Guohua An
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

2.  Investigation of pharmacokinetic and clinical outcomes of various meropenem regimens in patients with ventilator-associated pneumonia and augmented renal clearance.

Authors:  Sareh Razzazzadeh; Ilad Alavi Darazam; Mohammadreaza Hajiesmaeili; Jamshid Salamzadeh; Arash Mahboubi; Ehsan Sadeghnezhad; Zahra Sahraei
Journal:  Eur J Clin Pharmacol       Date:  2022-02-16       Impact factor: 2.953

Review 3.  Clinical Pharmacokinetics and Pharmacodynamics of Cefepime.

Authors:  Gwendolyn M Pais; Jack Chang; Erin F Barreto; Gideon Stitt; Kevin J Downes; Mohammad H Alshaer; Emily Lesnicki; Vaidehi Panchal; Maria Bruzzone; Argyle V Bumanglag; Sara N Burke; Marc H Scheetz
Journal:  Clin Pharmacokinet       Date:  2022-06-29       Impact factor: 5.577

Review 4.  Importance of Utilizing Natural Isotopologue Transitions in Expanding the Linear Dynamic Range of LC-MS/MS Assay for Small-Molecule Pharmacokinetic Sample Analysis - A Mini-review.

Authors:  Thanh Bach; Guohua An
Journal:  J Pharm Sci       Date:  2021-12-14       Impact factor: 3.784

5.  Aspects of matrix and analyte effects in clinical pharmacokinetic sample analyses using LC-ESI/MS/MS - Two case examples.

Authors:  Guohua An; Thanh Bach; Inas Abdallah; Demet Nalbant
Journal:  J Pharm Biomed Anal       Date:  2020-01-30       Impact factor: 3.935

6.  Development and validation of a volumetric absorptive microsampling- liquid chromatography mass spectrometry method for the analysis of cefepime in human whole blood: Application to pediatric pharmacokinetic study.

Authors:  Ganesh S Moorthy; Christina Vedar; Nicole R Zane; Kevin J Downes; Janice L Prodell; Mary Ann DiLiberto; Athena F Zuppa
Journal:  J Pharm Biomed Anal       Date:  2019-11-20       Impact factor: 3.935

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.